Abstract
Summary
Europe acute respiratory distress syndrome (ARDS) market is projected to register a substantial CAGR of 9.5% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2021, and the forecast period is 2022 to 2029
Market Segmentation:
Europe Acute Respiratory Distress Syndrome (ARDS) Market, By Cause (Coronavirus Disease 2019 (COVID-19), Sepsis, Inhalation of Harmful Substances, Severe Pneumonia, and Others), Type (Diagnosis and Treatment), Route of Administration (Oral, Parenteral, and Others), End User (Hospitals, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others), Country (Germany, France, U.K., Italy, Spain, Turkey, Hungary, Netherlands, Switzerland, Austria Lithuania, Poland, Russia, Ireland, Norway and Rest of Europe) Industry Trends and Forecast to 2029
Some of the major factors for the market growth of Europe acute respiratory distress syndrome (ARDS) are:
• Rise in the number of COVID-19 cases associated with ARDS
Market Players:
Some of the key market players for the Europe acute respiratory distress syndrome (ARDS) market are listed below:
• Gilead Sciences, Inc.
• Terumo Medical Corporation
• Getinge AB.
• LivaNova PLC
• Medtronic
• ResMed
• Fisher & Paykel Healthcare Limited.
• F. Hoffmann-La Roche Ltd
• Smiths Medical (part of ICU Medical, Inc.)
• Drägerwerk AG & Co. KGaA
• Fresenius SE & Co. KGaA
• Hamilton Medical
• Pfizer Inc.
• EUROSETS
• Armstrong Medical
• nice Neotech Medical Systems Pvt. Ltd.
Table of Contents
1 INTRODUCTION 21
1.1 OBJECTIVES OF THE STUDY 21
1.2 MARKET DEFINITION 21
1.3 OVERVIEW OF EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET 21
1.4 LIMITATIONS 23
1.5 MARKETS COVERED 23
2 MARKET SEGMENTATION 25
2.1 MARKETS COVERED 25
2.2 GEOGRAPHICAL SCOPE 26
2.3 YEARS CONSIDERED FOR THE STUDY 26
2.4 CURRENCY AND PRICING 26
2.5 DBMR TRIPOD DATA VALIDATION MODEL 27
2.6 MULTIVARIATE MODELLING 30
2.7 CAUSE LIFELINE CURVE IN EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET 31
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 32
2.9 DBMR MARKET POSITION GRID 33
2.10 MARKET END USER COVERAGE GRID 35
2.11 VENDOR SHARE ANALYSIS 36
2.12 SECONDARY SOURCES 37
2.13 ASSUMPTIONS 37
3 EXECUTIVE SUMMARY 38
4 PREMIUM INSIGHTS 40
4.1 PESTEL 41
4.2 PORTER'S FIVE FORCES 42
4.3 PIPELINE ANALYSIS 43
4.4 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: REGULATIONS 45
4.4.1 REGULATION IN EUROPE: 45
4.5 INSURANCE REIMBURSEMENT 47
4.5.1 CERN HEALTH INSURANCE SCHEME 47
5 MARKET OVERVIEW 48
5.1 DRIVERS 50
5.1.1 INCREASING PREVALENCE AND INCIDENCE OF ACUTE LUNG INJURY 50
5.1.2 WIDE RANGE OF RISK FACTORS FOR ARDS 50
5.1.3 ACCELERATION IN PATIENT POOL OF COVID-19 WITH ARDS 50
5.1.4 RISING RATE OF AIR POLLUTION AND LIFESTYLE-RELATED DISEASES 51
5.1.5 INCREASING ACCIDENT RATES AND TRAUMA CAUSING ARDS 51
5.2 RESTRAINTS 52
5.2.1 COMPLICATIONS ASSOCIATED WITH TREATMENTS 52
5.2.2 HIGH COST OF DEVICE AND TREATMENTS 52
5.2.3 LACK OF SKILLED WORKFORCE 53
5.3 OPPORTUNITIES 53
5.3.1 GROWING GERIATRIC POPULATION 53
5.3.2 RISING HEALTHCARE EXPENDITURE 54
5.3.3 STRATEGIC INITIATIVES BY MARKET PLAYERS 54
5.3.4 IMPROVING AWARENESS REGARDING ARD SYNDROME 55
5.4 CHALLENGES 55
5.4.1 STRINGENT RULES & REGULATIONS 55
5.4.2 MULTIPLE CHALLENGES FACED BY ICU NURSES 56
6 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE 57
6.1 OVERVIEW 58
6.2 CORONAVIRUS DISEASE 2019 (COVID-19) 60
6.3 SEPSIS 61
6.4 INHALATION OF HARMFUL SUBSTANCES 61
6.5 SEVERE PNEUMONIA 62
6.6 OTHERS 62
7 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE 63
7.1 OVERVIEW 64
7.2 DIAGNOSIS 66
7.2.1 IMAGING TESTS 67
- 7.2.1.1 CHEST X-RAY 68
- 7.2.1.2 CT SCAN 68
- 7.2.1.3 ULTRASOUND 68
- 7.2.1.4 OTHERS 68
7.2.2 BLOOD TEST 68
7.2.3 RESPIRATORY RATE 68
7.2.4 SPO2 TEST 68
7.2.5 OTHERS 68
7.3 TREATMENT 68
7.3.1 MECHANICAL VENTILATION 69
- 7.3.1.1 HIGH-FLOW NASAL O2 70
- 7.3.1.2 BI-LEVEL POSITIVE AIRWAY PRESSURE 70
- 7.3.1.3 CONTINOUS POSITIVE AIRWAY PRESSURE 70
- 7.3.1.4 PRONE POSITIVE VENTILATION 70
- 7.3.1.5 OTHERS 70
7.3.2 CORTICOSTEROIDS 70
- 7.3.2.1 METHYLPREDNISOLONE 71
- 7.3.2.2 DEXAMETHASONE 71
- 7.3.2.3 OTHERS 71
7.3.3 ANTIVIRAL MEDICATION 71
- 7.3.3.1 REMDESIVIR 72
- 7.3.3.2 COMBINATION DRUGS 72
- 7.3.3.3 OTHERS 72
7.3.4 EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) 72
7.3.5 TOCILIZUMAB 72
7.3.6 OTHERS 72
8 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION 73
8.1 OVERVIEW 74
8.2 PARENTERAL 76
8.2.1 INTRAVENOUS 77
8.2.2 INTRAMUSCULAR 77
8.3 ORAL 77
8.4 OTHERS 78
9 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER 79
9.1 OVERVIEW 80
9.2 HOSPITALS 82
9.3 SPECIALTY CLINICS 83
9.4 HOME HEALTHCARE 83
9.5 OTHERS 83
10 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL 85
10.1 OVERVIEW 86
10.2 DIRECT TENDER 88
10.3 HOSPITAL PHARMACY 89
10.4 RETAIL PHARMACY 89
10.5 ONLINE PHARMACY 89
11 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY COUNTRY 91
11.1 EUROPE 91
11.1.1 GERMANY 101
11.1.2 FRANCE 105
11.1.3 U.K. 109
11.1.4 ITALY 113
11.1.5 SPAIN 117
11.1.6 TURKEY 121
11.1.7 HUNGARY 125
11.1.8 NETHERLANDS 129
11.1.9 SWITZERLAND 133
11.1.10 AUSTRIA 137
11.1.11 LITHUANIA 141
11.1.12 POLAND 145
11.1.13 RUSSIA 149
11.1.14 IRELAND 153
11.1.15 NORWAY 157
11.1.16 REST OF EUROPE 161
12 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: COMPANY LANDSCAPE 162
12.1 COMPANY SHARE ANALYSIS: EUROPE 162
13 SWOT ANALYSIS 163
14 COMPANY PROFILE 164
14.1 GILEAD SCIENCES INC. 164
14.1.1 COMPANY SNAPSHOT 164
14.1.2 REVENUS ANALYSIS 164
14.1.3 PRODUCT PORTFOLIO 165
14.1.4 RECENT DEVELOPMENT 165
14.2 TERUMO CORPORATION 166
14.2.1 COMPANY SNAPSHOT 166
14.2.2 REVENUS ANALYSIS 166
14.2.3 PRODUCT PORTFOLIO 167
14.2.4 RECENT DEVELOPMENT 167
14.3 GETINGE AB 168
14.3.1 COMPANY SNAPSHOT 168
14.3.2 REVENUS ANALYSIS 168
14.3.3 PRODUCT PORTFOLIO 169
14.3.4 RECENT DEVELOPMENT 169
14.4 LIVANOVA PLC 170
14.4.1 COMPANY SNAPSHOT 170
14.4.2 REVENUE ANALYSIS 170
14.4.3 PRODUCT PORTFOLIO 171
14.4.4 RECENT DEVELOPMENTS 171
14.5 MEDTRONIC 172
14.5.1 COMPANY SNAPSHOT 172
14.5.2 REVENUE ANALYSIS 172
14.5.3 PRODUCT PORTFOLIO 173
14.5.4 RECENT DEVELOPMENTS 173
14.6 ARMSTRONG MEDICAL 174
14.6.1 COMPANY SNAPSHOT 174
14.6.2 PRODUCT PORTFOLIO 174
14.6.3 RECENT DEVELOPMENT 174
14.7 DRÄGERWERK AG & CO. KGAA 175
14.7.1 COMPANY SNAPSHOT 175
14.7.2 REVENUE ANALYSIS 175
14.7.3 PRODUCT PORTFOLIO 176
14.7.4 RECENT DEVELOPMENTS 176
14.8 EUROSETS 177
14.8.1 COMPANY SNAPSHOT 177
14.8.2 PRODUCT PORTFOLIO 177
14.8.3 RECENT DEVELOPMENT 177
14.9 F. HOFFMANN-LA ROCHE LTD 178
14.9.1 COMPANY SNAPSHOT 178
14.9.2 RECENT ANALYSIS 178
14.9.3 PRODUCT PORTFOLIO 179
14.9.4 RECENT DEVELOPMENTS 179
14.10 FISHER & PAYKEL HEALTHCARE LIMITED 180
14.10.1 COMPANY SNAPSHOT 180
14.10.2 REVENUE ANALYSIS 180
14.10.3 PRODUCT PORTFOLIO 181
14.10.4 RECENT DEVELOPMENTS 181
14.11 FRESENIUS SE & CO. KGAA 182
14.11.1 COMPANY SNAPSHOT 182
14.11.2 REVENUS ANALYSIS 182
14.11.3 PRODUCT PORTFOLIO 183
14.11.4 RECENT DEVELOPMENTS 183
14.12 HAMILTON MEDICAL 184
14.12.1 COMPANY SNAPSHOT 184
14.12.2 PRODUCT PORTFOLIO 184
14.12.3 RECENT DEVELOPMENT 184
14.13 NICE NEOTECH MEDICAL SYSTEMS PVT.LTD. 185
14.13.1 COMPANY SNAPSHOT 185
14.13.2 PRODUCT PORTFOLIO 185
14.13.3 RECENT DEVELOPMENT 185
14.14 PFIZER INC. 186
14.14.1 COMPANY SNAPSHOT 186
14.14.2 REVENUS ANALYSIS 186
14.14.3 PRODUCT PORTFOLIO 187
14.14.4 RECENT DEVELOPMENT 187
14.15 RESMED 188
14.15.1 COMPANY SNAPSHOT 188
14.15.2 REVENUE ANALYSIS 188
14.15.3 PRODUCT PORTFOLIO 189
14.15.4 RECENT DEVELOPMENT 189
14.16 SMITHS MEDICAL 190
14.16.1 COMPANY SNAPSHOT 190
14.16.2 REVENUS ANALYSIS 190
14.16.3 PRODUCT PORTFOLIO 191
14.16.4 RECENT DEVELOPMENTS 191
15 QUESTIONNAIRE 192
16 RELATED REPORTS 196